Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: Application to a pharmacokinetic study

- Highly selective method for the determination of ibrutinib, PCI-45227 and lenalidomide in plasma.
- This is the first LC-MS/MS-based method for simultaneous determination of ibrutinib, PCI-45227 and lenalidomide in plasma.
- Plasma sample clean-up involves a simple liquid-liquid extraction procedure.
- The developed LC-MS/MS based method was applied successfully for pharmacokinetic study.